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Tjebbe W. Galema, MD, PHD,* Marcel L. Geleijnse, MD, PHD,* Arie-Pieter Kappetein, MD, PHD,z
Peter P. de Jaegere, MD, PHD*A 79-year-old man with prior surgical aorticvalve replacement was admitted with acuteheart failure. Diagnostic work up revealed a
degenerated 25-mm Carpentier-Edwards aortic bio-
prosthesis with severe stenosis. The calculated Soci-
ety of Thoracic Surgery predicted risk of mortality
was 21.9%. The multidisciplinary heart team reached
consensus for transcatheter valve replacement in
the failing aortic bioprosthesis. The Lotus valve (Bos-
ton Scientiﬁc, Natick, Massachusetts) allows for a
controlled mechanical deployment and is completely
repositionable and retrievable even after full expan-
sion (1). The 25-mm Carpentier-Edwards biopros-
thesis has a true inner diameter—encompassing the
leaﬂet tissue mounted within the stent—of 21 mm
and therefore should accommodate a 23-mm Lotus
transcatheter heart valve (2). Because of mild-
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sitioned 2 mm more aortic, improving coaxial
alignment and sealing. Mean transvalvular gradient
was 11 mm Hg with only trivial paravalvular AR
(Figure 1). Transcatheter aortic valve replacement is
a valuable treatment strategy for patients with a
failing aortic bioprosthesis although residual para-
prosthetic regurgitation, and higher transvalvular
gradients may limit overall success (3). This report
illustrates the proof of concept of the intrinsic repo-
sitionable/retrievable features of the Lotus valve in
a degenerated aortic bioprosthesis.
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FIGURE 1 Transcatheter Lotus Valve Implantation in a Degenerated Bioprosthesis
The upper panel illustrates the failing 25-mm Carpentier-Edwards bioprosthesis with degenerated leaﬂets clearly visible on the transesophageal echo-
cardiogram (TEE) X-plane image. On the right side, a crimped Lotus valve is seated in the left ventricular outﬂow tract. Themiddle panel displays the initial
complete Lotus valve deployment. By TEE X-plane, mild-to-moderate paravalvular regurgitation is noted. The lower panel demonstrates the ﬁnal state
after repositioning the Lotus valve 2 mm higher towards the aorta with only trivial paravalvular aortic regurgitation by TEE. Note the difference in position of
the Lotus valve relative to the Carpentier-Edwards bioprosthesis before and after repositioning (arrow) and its tantalum marker relative to the Carpentier-
Edwards post (circle).
Van Mieghem et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 2 , 2 0 1 5
Lotus in a Degenerated Bioprosthesis F E B R U A R Y 2 0 1 5 : e 2 7 – 8
e28RE F E RENCE S1. Meredith IT, Worthley SG, Whitbourn RJ, et al.
Transfemoral aortic valve replacement with the
repositionable lotus valve system in high surgical
risk patients: The REPRISE I study. Euro-
Intervention 2014;9:1264–70.
2. Bapat VN, Attia R, Thomas M. Effect of valve
design on the stent internal diameter of abioprosthetic valve: a concept of true internal
diameter and its implications for the valve-
in-valve procedure. J Am Coll Cardiol Intv
2014;7:115–27.
3. Dvir D, Webb J, Brecker S, et al. Transcatheter
aortic valve replacement for degenerative bio-
prosthetic surgical valves: results from the globalvalve-in-valve registry. Circulation 2012;126:
2335–44.
KEY WORDS aortic stenosis, failed
bioprosthesis, TAVI
